The Weekly Term Sheet (2026-W47)

Seventy-three items were recorded, besides a fund close and the Genomics extension with Vertex, which are named and not counted; three of them appear under two headings below, so the category counts add up to 76.

The Weekly Term Sheet (2026-W47)

Johnson & Johnson agreed to buy Ollin Biosciences for USD 2.2bn upfront, with Blackstone Life Sciences funding USD 750m of the Phase 3 programme of OLN324 for single-digit royalties, and Lilly agreed to buy Calytrix for up to USD 1.5bn. Pfizer took three in vivo CAR-T programmes from Starna Therapeutics for USD 330m upfront, Isomorphic Labs raised a USD 5bn Series C and Soleus Capital agreed to buy 80 per cent of BioLineRx's royalty on APHEXDA. The FDA declined ivonescimab and Capricor's deramiocel.

Royalty and revenue-share rates on the 42 streams touched between 15 and 22 November, 27 of them with a published rate or band. Word bands are converted to ranges. Nippon Shinyaku's share of 30 to 50 per cent of US deramiocel revenue to Capricor runs off the scale, Aytu's 28 per cent of EXXUA revenue to Fabre-Kramer, rising to 39 per cent, is the highest royalty on the axis, and Soleus Capital's 14.4 per cent of APHEXDA sales is 80 per cent of BioLineRx's 18 per cent royalty.


Highlights

Royalty events: 9 created and 17 existing streams moved. Blackstone Life Sciences takes single-digit royalties on Johnson & Johnson's OLN324 in return for funding its Phase 3 programme, and Sanofi will owe Seawolf, and Lilly Stipple Bio, tiered royalties.

ProMIS will owe Ossianix royalties, as will Dewpoint to Cancer Research UK, Pfizer to Starna Therapeutics, AbbVie to DISCO Pharmaceuticals and Merck to Isomorphic Labs, at undisclosed rates. Arcera Life Sciences will owe Innogen tiered royalties of up to double digits on efsubaglutide alfa in its emerging-market territory. Soleus Capital agreed to buy 80 per cent of BioLineRx's royalty on APHEXDA.

Kyorin's agreement with Acadia opens a route to Japanese sales of DAYBUE, on which Acadia owes Neuren a royalty outside North America. Merck reported a survival benefit for sac-TMT, licensed from Kelun-Biotech, which carries a Blackstone Life Sciences royalty, and the FDA delayed its decisions on Savara's molgramostim, on which RTW would buy a royalty, and on Belite Bio's tinlarebant, on which Belite owes Columbia University a royalty.

The FDA declined ivonescimab and Capricor's deramiocel, on which Nippon Shinyaku would pay Capricor a share of US revenue, and approved new aficamten label data.

CG Oncology reported a positive Phase 3 for cretostimogene, SELLAS a positive Phase 3 for galinpepimut-S and Zelgen a positive pivotal interim analysis for ZG006, licensed to AbbVie outside Greater China, each carrying a stated royalty.

The European Commission approved daraxonrasib, which opens the ex-US term of the Royalty Pharma royalty on Revolution Medicines' drug, and senaparib, on which Pharmanovia owes IMPACT Therapeutics royalties. The Commission also approved olezarsen, on which Sobi owes Ionis a royalty, and Brazil approved tegoprazan, on which RaQualia shares in what HK inno.N receives from Eurofarma.

The FDA approved Regeneron's cemdisiran, which starts Alnylam's royalty and approval milestone, and accepted AstraZeneca's application for sonesitatug vedotin, on which AstraZeneca owes KYM Biosciences royalties, with Priority Review.

M&A and restructuring: 12 (8 agreed or completed, 2 terminated, 1 wind-down, 1 restructuring). Johnson & Johnson agreed to buy Ollin Biosciences for USD 2.2bn upfront, Lilly to buy Calytrix for up to USD 1.5bn, Merck KGaA to buy Rapid Micro Biosystems and Medtronic to buy Contego Medical.

Gedeon Richter agreed to buy Mayne Pharma, its US licensee for an estetrol contraceptive, for about USD 428m, and Rosemont Pharmaceuticals to buy Aytu BioPharma for about USD 56m.

Astromech bought Form Bio, a fellow Colossal Biosciences company, in shares valued at USD 230m. A Hong Kong-listed laboratory group dropped its purchase of a preclinical research organisation, and Genetic Signatures dropped its proposed merger with Microba Life Sciences after Microba said it could not fund it; its largest shareholder has since set terms on which it would back a revived merger.

HLB agreed to absorb its affiliate HLB Life Science in shares worth about USD 190m to bring the rights and income from rivoceranib into one company, and Tanabe Pharma decided to wind down its Israeli subsidiary NeuroDerm. ExpreS2ion will cut its staff from 21 to five to fund its lead cancer vaccine to a Phase 1 readout.

Licence-outs and asset acquisitions: 11. Kyorin took exclusive Japanese sales rights to Acadia's Rett syndrome drug DAYBUE STIX for USD 30m upfront, up to USD 45m in milestones and a share of net sales for Acadia. Sanofi licensed Seawolf's programmes, Meiji Seika took an Arcturus vaccine licence with a USD 50m share purchase, and Biogen took an option on a TRIMTECH programme.

Lilly took worldwide rights to the products of a research collaboration with Stipple Bio for up to USD 5.9bn in milestones and tiered royalties. ProMIS licensed Ossianix's brain-shuttle technology for its Alzheimer's antibody, and Cancer Research UK will fund and run the first trial of Dewpoint's MYC condensate modulator for milestones and royalties.

Pfizer took rights outside Greater China to three in vivo CAR-T programmes from Starna Therapeutics for USD 330m upfront and up to USD 2.3bn in milestones. AbbVie took options on AND-gated bispecific antibodies from DISCO Pharmaceuticals for USD 40m upfront and up to USD 2.5bn in option and milestone payments.

Innogen licensed efsubaglutide alfa to Arcera Life Sciences for parts of Africa, Latin America, the Middle East and Eastern Europe for USD 15m upfront, and Merck agreed an oncology research collaboration with Isomorphic Labs.

Vertex extended its target-discovery collaboration with Genomics; the extension is named and not counted.

Regulatory: 18. The FDA declined to approve ivonescimab, which Summit licenses from Akeso against milestones and a low double-digit royalty. It approved IGALMI for at-home use, before the date that earns the BioXcel estate a milestone, and added head-to-head data to the aficamten label.

Japan approved a boron neutron capture therapy drug in a second indication, and the European Commission approved daraxonrasib in pancreatic cancer, senaparib in ovarian cancer and olezarsen in severe hypertriglyceridaemia.

Brazil approved tegoprazan in three indications, and the Commission approved Adcomfo, an omalizumab biosimilar developed by Kashiv BioSciences, now part of Amneal, with Alvotech.

The FDA approved Beren's adrabetadex in Niemann-Pick disease type C, with a priority review voucher, and GSK's neladalkib, acquired with Nuvalent, in ALK-positive lung cancer, neither with a stated royalty.

On 18 November the FDA also approved Regeneron's cemdisiran, licensed from Alnylam, in generalised myasthenia gravis, and Sanofi's venglustat, the first treatment for the neurological manifestations of type 3 Gaucher disease.

On 19 November the FDA accepted AstraZeneca's application for sonesitatug vedotin, licensed from KYM Biosciences, with Priority Review, and the European Commission approved Sanofi's rabies vaccine VaxRabeo. On 20 November Savara said the FDA would not act on molgramostim by its 22 November date, and Belite Bio that the FDA had extended its review of tinlarebant by three months. Late that evening Capricor said the FDA had declined deramiocel in Duchenne muscular dystrophy.

Clinical: 7. Helus reported a positive Phase 3 for its psilocin analogue in depression, and CG Oncology a positive registrational Phase 3 for cretostimogene in bladder cancer. AriBio's oral AR1001 met the primary endpoint of its Phase 3 in Alzheimer's disease in the monotherapy population only, which starts a 90-day window for Fosun to take worldwide rights.

SELLAS reported a survival benefit in the Phase 3 REGAL trial of galinpepimut-S in acute myeloid leukaemia, and Zelgen said a pivotal trial of ZG006 in small cell lung cancer met its primary endpoint at an interim analysis.

Actinogen said its pivotal trial of emestedastat in Alzheimer's disease missed its primary endpoint. Merck said sac-TMT, licensed from Kelun-Biotech, improved overall survival in a Phase 3 trial in gastro-oesophageal adenocarcinoma.

Structured capital: 3. Blackstone Life Sciences agreed USD 750m of development funding for OLN324, Akebia took a senior secured term loan of up to USD 140m from Symbiotic Capital, and Soleus Capital agreed to buy most of BioLineRx's APHEXDA royalty for USD 5.6m.

Private funding: 10. Isomorphic Labs raised a USD 5bn Series C, Science Corporation a USD 400m Series D, Marrow Therapeutics launched with USD 173m, VitriVax a USD 87m Series C, Onward Therapeutics closed a USD 28m Series B, Bravera Bio raised a USD 171.1m Series A, Galvanize Therapeutics USD 130m, Seawolf Therapeutics USD 100m, Remedy Robotics USD 62m and Commit Biologics a USD 60m seed round. Sofinnova Partners closed its second crossover fund at about USD 815m; it is not counted.

Public capital: 7. JW Therapeutics agreed a share subscription, Jiangsu Recbio agreed a subscription with Yangtze River Pharmaceutical, Sinotau Pharmaceutical launched its Hong Kong offering, and Meiji Seika bought USD 50m of Arcturus shares at a premium.

Lytix Biopharma raised about USD 7.8m in Oslo, and SELLAS raised USD 172.5m in a public offering, including the underwriters' option, after its Phase 3 result. Crystal Crop Protection, an Indian agrochemicals and seeds company, ran its initial public offering on the NSE and BSE.

Courts: 8. Genentech, Roche and PTC Therapeutics sued Zydus over its application for generic EVRYSDI tablets, a product on which Royalty Pharma and PTC hold the royalty, and Astellas and two Pfizer subsidiaries sued Apotex over generic Xtandi tablets, on which Royalty Pharma holds a royalty. Baxter sued Sagent and Gland Pharma over an approved generic of its premixed norepinephrine, which Sagent plans to launch from 1 December. The Patents Court in London held Boehringer's UK compound patent and supplementary protection certificate on empagliflozin invalid.

The Munich Higher Regional Court lifted the preliminary injunction that had stopped Merck launching Keytruda SC in Germany on Halozyme's MDASE patents, and the Delaware Supreme Court affirmed the dismissal of an investor's suit over a patent application that Vividion released to Scripps before its sale to Bayer.

Vanda settled its suit against MSN over generic HETLIOZ LQ with a royalty-free licence from the first quarter of 2040. Bayer sued MSN over its application for generic STIVARGA, on which Amgen reported a royalty on Bayer's sales.

Rate disclosure across the window: 6 hard numbers and 21 bands. Royalty Pharma takes 4.5 per cent of aficamten sales up to USD 5.0bn and 1 per cent above, and 4.55 per cent of daraxonrasib sales up to USD 2.0bn, 2.50 per cent to USD 4.0bn and 1.00 per cent to USD 8.0bn.

Aytu pays Fabre-Kramer 28 per cent of EXXUA net revenue, rising to 39 per cent above USD 300m a year. Ayrmid pays BioLineRx 18 per cent of APHEXDA net sales, of which Soleus Capital is buying 14.4 percentage points. Summit owes Akeso low double-digit royalties, Acadia owes Neuren the mid-teens to the low twenties outside North America, and Blackstone takes single-digit royalties on OLN324.

Sanofi pays Cytokinetics low to high teens on aficamten in China and Taiwan. CG Oncology owes Kissei a low single-digit royalty on US sales and receives the mid-twenties from Kissei in Japan and high single digits from Lepu in China.

Pharmanovia owes IMPACT Therapeutics tiered royalties up to the mid-twenties on senaparib, Sobi owes Ionis a tiered royalty up to the mid-twenties on olezarsen, and Fosun would owe AriBio a low double-digit royalty on AR1001 if it exercises its option. SELLAS owes Memorial Sloan Kettering a mid-single-digit royalty on galinpepimut-S and receives high single digits to low double digits from 3D Medicines in Greater China. AbbVie owes Zelgen tiered royalties from the high single digits to the mid double digits on ZG006 outside Greater China.

Verrica owes Lytix tiered royalties from the low double digits to the mid-teens on VP-315, Regeneron owes Alnylam tiered double-digit royalties of up to 15 per cent on cemdisiran, Arcera will owe Innogen tiered royalties of up to double digits on efsubaglutide alfa, AstraZeneca owes KYM Biosciences tiered royalties up to low double digits on sonesitatug vedotin, and Royalty Pharma holds a royalty of slightly less than 4 per cent on Xtandi. Amgen reported in 2014 a 20 per cent royalty on Bayer's Stivarga sales.

Savara would pay RTW 7.0 per cent to 1.0 per cent of US net sales of MOLBREEVI, the top tier rising to 9.5 per cent if sales miss a set level, once RTW pays on approval. Belite Bio owes Columbia University single-digit royalties on tinlarebant, and Blackstone Life Sciences takes low-to-mid single-digit royalties on sac-TMT. Subject to approval, Capricor would receive a share of US deramiocel revenue of between 30 and 50 per cent from Nippon Shinyaku.

The nine royalties created in the window, by what each publishes. None publishes a rate, two a band (Blackstone's single-digit royalties on OLN324 and Innogen's tiered royalties of up to double digits from Arcera), and seven, among them Pfizer's royalty to Starna and AbbVie's to DISCO, no rate at all. Across the window the issue counts 6 hard numbers and 21 bands.

Tracked royalty buyers inside the window: 2. Blackstone Life Sciences will pay USD 750m over several years to fund the Phase 3 programme of OLN324 for milestones and single-digit royalties, subject to the closing of the Ollin acquisition.

Soleus Capital will pay USD 5.6m for 80 per cent of BioLineRx's 18 per cent royalty on APHEXDA, subject to Ayrmid's consent, with closing expected on or about 30 November.

Open at the start of the window. The tender offer for Pacira, which started on 30 October. Peach Purchaser, a Viatris subsidiary, filed its offer to purchase at "$36.50 per Share, to the seller thereof in cash", expiring on 16 November, and Pacira's board recommended acceptance in its Schedule 14D-9.

The waiting period under the HSR Act expired on 29 October. Viatris said in its third-quarter release of 5 November that "The transaction is expected to close by the end of November 2026", and its quarterly report of the same day that it "expects to fund the transaction primarily from excess cash with the remainder from short-term borrowings".

Pacira's first amendment to its Schedule 14D-9, filed on 3 November, adds employee materials and leaves the terms unchanged. Pacira said on 5 November that it "will not issue an earnings release for the quarterly period ended September 30, 2026, nor will it hold a conference call" and is withdrawing its 2026 guidance.

Pacira's quarterly report of the same day sets the fee it would owe Viatris on termination at "$ 62.0 million" and carries the Flexion contingent value rights at USD 3.0m, against payments that "could aggregate up to a total of $ 372.3 million" on milestones reached by 31 December 2030.

Pacira's tender offer expired at the end of 16 November, Eastern Time. Viatris's amendment of 12 November leaves the USD 36.50 price and the expiry unchanged and only updates the litigation passage: two stockholder complaints, Carroll v. Pacira BioSciences (Index No. 656215/2026) and Burke v. Pacira BioSciences (Index No. 656243/2026), and "fifteen demand letters".

Pacira's amendment to its Schedule 14D-9 of the same day adds that "The Pacira Defendants have not been served with the Complaints."

Pacira also disclosed the same evening that the Ninth Circuit, on 6 November, held "that the Company owes royalties on EXPAREL manufactured using its 200-liter process" to the Research Development Foundation. RDF "asserted that the issuance of that patent extends the Company's royalty obligations under the agreement until 2041"; Pacira is evaluating its legal options.

Viatris said on 17 November that it "has completed its acquisition of Pacira BioSciences, Inc." and expects it "to contribute total revenues of between $90 million and $100 million" from 17 November to 31 December. Its amendment of the same day states that "approximately 32,929,780 Shares were validly tendered and not validly withdrawn in the tender offer, representing approximately 66.46% of the total outstanding Shares".

Pacira's current report puts the cost of the offer, the merger and the repayment of certain debt at "approximately $1.69 billion"; its convertible notes due 2029 now convert into cash only. The offer is now completed and stays outside the counts.

The reopening of the terms of the Recordati offer, which ended on 9 November, with payment for the reopening due "on 17 November 2026" per the offeror's final results notice of 26 October. A notice of 6 November says the CVC Investor "directly holds a total of no. 13,008,136 Recordati shares, representing approximately 6.220%", with Respighi BidCo unchanged at about 74.581 per cent.

The offeror's notice of 7 November says the offeror and the CVC Investor together "would hold an aggregate shareholding consisting of 180,395,563 Shares", "representing 86.262% of the Issuer's share capital", and that the reopening would end on 9 November 2026.

The offeror's provisional results notice of the same evening says that 22,208,274 shares, "representing approximately 10.620% of the Issuer's share capital", were tendered in the reopening for about USD 1.37bn (EUR 1,177,038,522), and that the offeror and the CVC Investor will hold "approximately 91.928%".

The notice is headed "RECORDATI SHARES WILL BE DELISTED FROM EURONEXT MILAN": the offeror will use its right to purchase the remaining shares, "thereby implementing the Joint Procedure". Payment for the reopening was due on 17 November.

The offeror's final results notice of 13 November puts the holding at "approximately 91.923%" and sets the Joint Procedure on "the remaining aggregate maximum no. 16,890,530 Shares" at "Euro 53.00 for each Remaining Share", up to about USD 1.04bn (EUR 895,198,090) in all, on 24 November. Borsa Italiana will suspend the shares on 20 and 23 November and delist them "with effect from the trading session of Tuesday, 24 November 2026".

The offeror's settlement notice of 17 November says that "Respighi BidCo completed the settlement of the Offer in respect of a total of no. 22,208,274 Recordati shares tendered to the Offer during the Reopening of the Terms".

The CVC Investor contributed 13,072,398 shares to the offeror at no more than EUR 53.00 a share, and Respighi BidCo now "holds an aggregated shareholding consisting of no. 191,247,356 Recordati shares, representing approximately 91.451% of Recordati's share capital". The notice does not explain the difference from the 91.923% of 13 November.

The closing of the offering of about USD 125m priced in W45 by Precision BioSciences. Precision BioSciences' current report of 9 November restates the offering terms and does not report a closing. No closing of the Precision BioSciences offering had been filed by 22 November.

The closing of the term loan of up to USD 750m led by HealthCare Royalty for Rhythm Pharmaceuticals, on which the amendment of Rhythm's existing revenue interest financing agreement becomes effective.

Rhythm's third-quarter release describes "a five-year term loan facility led by KKR's HealthCare Royalty ("Healthcare Royalty") in partnership with Blackstone Life Sciences". No closing had been filed by 22 November.

The closing of the sale of mitazalimab by Alligator Bioscience to Biossil, agreed on 31 October, where "Closing is expected within 30 days of signing". No closing had been reported by 22 November; Alligator's financial calendar lists an extraordinary general meeting on 27 November.

The Karyopharm Chapter 11 sale process with Ayrmid as lead bidder (In re Karyopharm Therapeutics Inc., Bankr. S.D. Tex., No. 26-90827). A current report filed on 5 November says "Trading of the Company's common stock will be suspended on Nasdaq at the opening of business on November 11, 2026"; the company expects the transaction "to close in the first quarter of 2027", subject to court approval.

Its notice of late filing of 13 November confirms that "On November 11, 2026, the Nasdaq Stock Market (“Nasdaq”) suspended trading of the Company’s common stock."

The ANI Pharmaceuticals cash offer for Egetis Therapeutics, whose acceptance period "is expected to commence on or around 20 November 2026 and expire on or around 18 December 2026", per the Egetis board statement; neither the offer document nor the start of the acceptance period had been announced by 22 November.

Post-trial briefing in Exelixis's CABOMETYX patent case against MSN, after the bench trial that ended with closing arguments on 5 November, per the docket, where the minute entry of that day reads "The parties were directed to submit a stipulation and proposed order setting forth the agreed upon schedule".

A stipulation and an order followed on 9 November (D.I. 279 and 280), ten redacted documents and an exhibit list on 13 November (D.I. 281 to 291), and an oral order and a correcting entry on 16 November; none of these texts is public on the docket.

The Paradigm administrators said on 28 October that "the Supreme Court of Western Australia has approved a three (3) month extension of the convening period for the second meeting of creditors until 27 January 2027", after the hearing of 27 October; they expect to issue their report and convene the meeting "in the coming weeks".

In an announcement released on 18 November with the administrators' authorisation, Paradigm reported an independent interim analysis by TrialKey that supports a new trial of iPPS outside the United States.

It said that "The Board's proposal to preserve the iPPS program has not been presented to or approved by creditors" and that "Any proposed deed of company arrangement remains subject to the applicable creditor decision and other required approvals". No report to creditors or meeting date had been announced by 22 November.

The emergency motion connected to the BioXcel sale order and the appeal against the sale order, filed on 26 October, per the docket; the hearing of 30 October was cancelled by an agenda filed on 28 October, with no reason given in the docket text; the sale itself has completed.

The debtors filed a plan supplement on 13 November (D.I. 330), and the hearing on the plan is set for 3 December. On 16 November they filed the agenda for a hearing on 18 November (D.I. 332) and designated additional items for the record of the appeal (D.I. 334). The court signed an order approving the debtors' settlement with the Hills plaintiffs (D.I. 333) and an order authorising a change of corporate name (D.I. 339).

On 17 November an amended agenda marked the 18 November hearing as cancelled (D.I. 341). The texts are not public on the docket.

Teva announced the at-home approval of IGALMI on 16 November, before the 21 November date for the estate's milestone of up to USD 67.5m (Clinical and Regulatory).

The clearance of Labcorp's purchase of BioReference testing businesses from OPKO Health. Labcorp's quarterly report of 30 October says the deal "is anticipated to close mid-2027", and OPKO's quarterly report of 4 November that the parties may terminate "if the transaction has not closed by April 14, 2027". No clearance had been reported by 22 November.

The scheme document for Silence, the QIAGEN offer document after clearance by BaFin, and the closing of the initial public offering of Windward Bio. Windward Bio's amended registration statement of 9 November offers 10,294,117 common shares at a price "estimated to be between $16.00 and $18.00", and says "Sanofi has agreed to purchase, in a private placement, 1,532,691 common shares and pre-funded warrants to purchase 1,408,485 common shares for an aggregate purchase price of $50.0 million".

Windward Bio registered its common shares on the Nasdaq Stock Market after the close on 9 November, and Nasdaq filed its certification of the listing on 12 November. Windward Bio priced on 12 November at USD 17.00 a share, the middle of the range (W46, Public capital).

It closed the offering on 16 November: 11,838,234 common shares, "which includes the full exercise of the underwriters' option to purchase an additional 1,544,117 common shares", and the USD 50.0m private placement to Sanofi, for gross proceeds of "approximately $251.2 million".

Silence's quarterly report of 13 November says "The Transaction is expected to close in the first quarter of 2027"; neither a Silence proxy statement nor a QIAGEN Schedule TO had been filed on EDGAR by its close on 20 November.

The closings of the deals agreed in W46. argenx expects its purchase of Unnatural Products "to close by the end of the year, subject to customary closing conditions"; CorMedix expects its purchase of Heron's assets to close in the first quarter of 2027, subject to Heron's shareholder vote and HSR clearance.

Charles River expects its purchase of Frontage's bioanalysis and DMPK business in Exton, Pennsylvania, to close in the first half of 2027, MaxCyte expects its purchase of Akron BioProducts to close before the end of 2026, and Scholar Rock's sale of its rare paediatric disease voucher to BioNTech is subject to the expiry or termination of the HSR waiting period.

No closing had been reported by 22 November; CorMedix's filings of 16 November repeat a first-quarter 2027 closing for the Heron assets.

Dechra, which agreed in W46 to buy Gallant Pet, said on 17 November that it "today completed its acquisition of Gallant Pet Inc" and that "the terms of the transaction will remain confidential". The completion is not counted.

Shionogi, which agreed in W41 to buy IntraBio, said on 18 November that it "has completed the acquisition of IntraBio Inc." and "paid a lump sum of USD 2.0 billion to acquire all outstanding shares of IntraBio, including global intellectual property and commercialization rights for AQNEURSA"; Shionogi filed a notice on TDnet at the same time. The completion is not counted.

The closings of the offerings priced in W46 with delivery expected on or about 16 November, among them Windward Bio and Rezolute. Windward Bio, which filed its final prospectus on 16 November, closed its offering that evening (above). Rezolute filed a current report on its pricing that puts net proceeds at about USD 93.5m.

Vir Biotechnology, which priced its offering in W46, said in a current report of 16 November that the offering was expected to close that day. Neither Rezolute nor Vir had reported a closing by 22 November; a Vir filing of 16 November only adds an omitted filing-fee exhibit.

The FDA decisions due on Saturday 14 November on aficamten, IGALMI and ivonescimab have all been announced; the three are in Clinical and Regulatory.

The sale of the remaining assets in the Sangamo Chapter 11 case. The debtor's notice of 16 November (D.I. 605) says that by the bid deadline of 13 November it "received bids for certain subsets of the Remaining Assets" and "has adjourned the Auction and the Sale Hearing for the Remaining Assets to a date and time to be determined". The auction had been set for 17 November and the sale hearing for 23 November.

The notice also records that the debtor paid off its replacement DIP facility on 2 October. The other entries of 16 November are certificates of service (D.I. 591 and 597), the equity committee's joinder in support of extending the debtors' exclusive period (D.I. 592), the withdrawal of a certificate of mailing (D.I. 593), a notice of deposition (D.I. 594) and fee applications by counsel (D.I. 595, 596 and 598 to 604).

The only entry of 17 November is a change of address for counsel (D.I. 606). On 18 November the equity committee withdrew its notice of deposition of the creditors' committee (D.I. 607).

The debtor filed a certificate of no objection on its second omnibus motion to reject executory contracts and unexpired leases, which covers a lease, a van and copiers rather than licences (D.I. 608), and a certification of counsel on an order extending the time to assume or reject its nonresidential real property lease (D.I. 609).

The same day Raymond James, the debtor's investment banker, filed a supplement to its first interim fee application (D.I. 610), and the claims agent filed a certificate of service (D.I. 611).

The agenda for the hearing of 23 November (D.I. 612, filed 19 November) says the debtor "adjourned the auction and the Sale Hearing for the Remaining Assets to a date and time to be determined"; that hearing covers the extension of exclusivity.

The creditors' committee then "determined not to prosecute the Objection", and the debtor's certification of counsel (D.I. 619, filed 19 November) says "the Motion is uncontested"; the court entered the order on 20 November (D.I. 620), extending the exclusive period to file a plan "through and including December 23, 2026" and to solicit acceptances "through and including February 24, 2027".

The debtor's amended agenda (D.I. 621, filed 20 November) says: "AS NO MATTERS ARE SCHEDULED TO GO FORWARD, THE HEARING HAS BEEN CANCELLED WITH PERMISSION FROM THE COURT"; the sale motion for the Remaining Assets remains adjourned.

The other entries of 20 November are a fee application by the creditors' committee's counsel (D.I. 622), a supplement to the list of ordinary course professionals (D.I. 623) and a certificate of service (D.I. 624); no new auction date had been filed by 22 November.

Events dated after the close of the window, from the Recordati Joint Procedure and delisting on 24 November to the EU decision on Regeneron's cemdisiran, licensed from Alnylam, in the second half of 2027. Gold marks an event on a royalty-bearing stream or licence.


M&A and Restructuring

The window day by day, dated by primary release or filing. Monday 16 November carried three of the nine royalties created, among them Blackstone's royalty on Johnson & Johnson's OLN324, seven M&A items and seven clinical and regulatory items; Thursday 19 November the DISCO, Innogen and Isomorphic Labs royalties and three court items.

Gedeon Richter and Mayne Pharma: scheme at A$6.40 a share in cash, about USD 428m for the US licensee of Richter's estetrol pill (Monday 16 November)

Mayne Pharma Group (ASX: MYX), a US-focused specialty pharmaceutical company, said that it had signed a scheme implementation deed with Gedeon Richter (Budapest: RICHTER) at "A$6.40 per share in cash", about USD 4.54. Mayne sells the estetrol and drospirenone contraceptive NEXTSTELLIS in the United States, and Richter holds the estetrol franchise.

  • The price: the consideration "values Mayne Pharma's equity at approximately A$604 million", about USD 428m, a "99.4% premium to the pre-announcement share price".
  • The funding: "The Scheme is not subject to any financing condition, with Richter funding the acquisition out of its internal cash resources."
  • The conditions: FIRB approval, HSR clearance, a voluntary CFIUS declaration, the shareholder vote and court approval, and the completion of the sale of Mayne's International business segment to Evaris Pharma, announced on 6 November. Implementation is expected in March 2027.
  • The buyer's release: Richter's own release on the Budapest Stock Exchange says Mayne's three largest shareholders, "who currently collectively own 22.14% of the ordinary shares", intend to vote for the scheme absent a superior proposal, and sets the scheme meeting for late January 2027 and implementation for "Mid to late March 2027".
  • The fees: the deed sets the break fee and the reverse break fee at "$6 million" each, in Australian dollars, about USD 4.3m.
  • The advisers: Mayne appointed "Leerink Partners as sole financial adviser and Gilbert + Tobin and Arnold & Porter as legal advisers", and Richter "H.C. Wainwright & Co. as financial adviser and Johnson Winter Slattery and Hogan Lovells Cadwalader as legal advisers".
  • Instrument: scheme of arrangement for cash.
  • Royalty read-through: the deed refers to "royalty and milestone payment liabilities that have been Fairly Disclosed" without rates; Richter would buy the US licensee that owes them.

ADICON Holdings and Crown Bioscience (Monday 16 November). ADICON Holdings (HKEX: 9860), a clinical laboratory group, said that "As the Regulatory Approvals had not been obtained on or before the Outside Date", the buyer and the seller "mutually agreed to terminate the Share Purchase Agreement with immediate effect" on 13 November after trading hours, so its purchase of all the shares of the preclinical research organisation Crown Bioscience International, announced on 13 November 2025, "will not proceed".

The announcement adds that "none of the Buyer, the Seller or the Target Company shall have any further obligation or liability to one another thereunder". Instrument: termination of a share purchase agreement at the outside date. Royalty read-through: none.

Lilly and Calytrix Bio (Monday 16 November). Calytrix Bio, a private company developing a biparatopic antibody against mutant calreticulin for essential thrombocythaemia and myelofibrosis, said that Lilly will acquire it and that "Calytrix shareholders could receive up to $1.5 billion in cash, inclusive of an upfront payment and subsequent payments upon the achievement of certain clinical and regulatory milestones".

The upfront payment is not disclosed. Centerview Partners and Goodwin Procter advise Calytrix, and Paul, Weiss, Rifkind, Wharton & Garrison advises Lilly. Instrument: acquisition for cash with clinical and regulatory milestones. Royalty read-through: none stated in the release.

Merck KGaA and Rapid Micro Biosystems (Monday 16 November). Rapid Micro Biosystems (Nasdaq: RPID), which makes automated microbial quality-control systems, agreed to be acquired by Merck KGaA, Darmstadt, Germany "at a price of $0.75 per share in an all-cash transaction" by tender offer.

The transaction "is expected to close in December 2026"; neither release states an equity value. Perella Weinberg Partners and Goodwin Procter advise Rapid Micro Biosystems. Its quarterly report of 19 November names the buyer as EMD Holdings NewCo II, sets the fee Rapid Micro Biosystems would owe on termination at "$ 1.6 million", and reports a Nasdaq notice of 16 November that its share price had "closed below $1.00 per share".

Instrument: cash tender offer. Royalty read-through: none.

Medtronic and Contego Medical (Monday 16 November). Medtronic (NYSE: MDT) agreed to acquire Contego Medical, a maker of carotid stenting systems. The deal is "Valued at $380 million with potential payments post-acquisition" and is expected to complete in Medtronic's third fiscal quarter. Instrument: acquisition with contingent payments. Royalty read-through: none.

Rosemont Pharmaceuticals and Aytu BioPharma (Monday 16 November). Rosemont Pharmaceuticals, a UK maker of oral liquid medicines backed by Inflexion, agreed to acquire Aytu BioPharma (Nasdaq: AYTU) by tender offer at USD 2.70 a share in cash, "a 41.1% premium to Aytu's 30-day volume-weighted average share price".

Aytu's release puts the total at "approximately $56 million on a fully-diluted basis", with closing expected in "late December 2026"; there is no contingent value right. Canaccord Genuity and Dorsey & Whitney advise Aytu, and Bourne Partners and Ropes & Gray advise Rosemont.

Aytu's quarterly report says it pays Fabre-Kramer on the antidepressant EXXUA "initially 28 % of net revenue and increasing to 39 % if net revenue exceeds $ 300.0 million in any year". Instrument: cash tender offer followed by a merger. Royalty read-through: Rosemont would take on the EXXUA royalty owed to Fabre-Kramer.

Astromech and Form Bio (Tuesday 17 November). Astromech, an AI company building predictive models of biological change, announced "the acquisition of Form Bio in an all-stock transaction valued at $230 million". Form Bio designs genetic medicines and assesses their manufacturability; Astromech takes its "intellectual property, selected contracts and assets, and team".

"Both companies are part of the Colossal Biosciences ecosystem." Instrument: all-stock acquisition of assets and team. Royalty read-through: none stated.

Genetic Signatures and Microba Life Sciences (Tuesday 17 November). Genetic Signatures (ASX: GSS), a molecular diagnostics company, said that it "has resolved not to proceed with the Proposed Merger with Microba Life Sciences Limited (ASX: MAP)" after Microba said it "will not have financial capacity to complete the Proposed Merger without additional capital". Genetic Signatures had discussed providing unsecured debt funding to Microba, but its board "was not prepared to proceed with such an arrangement".

Microba said on 18 November that "The Proposed Merger will therefore not proceed" and that it "is exploring its options for funding whilst it remains in voluntary suspension".

BCAL Diagnostics (ASX: BDX), the largest shareholder of Genetic Signatures, said on 19 November that it would consider supporting the merger on revised terms that "would need to specify (amongst other things) a 60:40 merger ratio in favour of GSS and GSS being provided a 'fiduciary out'". It "would also consider providing funding to MAP of up to $2 million", about USD 1.4m, which depends on BCAL raising capital itself and on "the resignation of the GSS Chair".

Genetic Signatures said on 19 November that a non-executive director, Dr Jenny Harry, had resigned with effect from 20 November "In light of recent developments at Genetic Signatures"; its Chair, Mike Aicher, remains. Neither company had responded to BCAL's terms by 22 November. Instrument: terminated merger proposal. Royalty read-through: none.

HLB and HLB Life Science (Thursday 19 November). HLB (KOSDAQ: 028300) filed its decision to absorb HLB Life Science (KOSDAQ: 067630), an affiliate in which it holds 16.98 per cent, so as to "리보세라닙(Rivoceranib) 관련 권리ㆍ수익 구조를 일원화하고 지배구조를 단순화하여" (unify the rights and revenue structure relating to rivoceranib and simplify governance). HLB will issue 8,674,057 new shares, 0.0857532 for each HLB Life Science share, at a merger value of KRW 30,063 a share, about USD 190m (KRW 260.8bn) in all.

The filing says the combined company can manage "리보세라닙(Rivoceranib)의 수익 구조와 판권 및 실시권 등을" (the revenue structure, marketing rights and licence rights of rivoceranib) together. HLB Life Science shareholders vote on 30 March 2027 and the merger date is 1 July 2027; HLB shareholders holding 20 per cent can block it as a small-scale merger between 4 and 18 December.

A first attempt was approved by HLB Life Science shareholders in July 2025 and withdrawn on 1 August 2025, when the appraisal payments owed to dissenting shareholders "당초 계약상 상한선이었던 400억원을 넘어선다" (exceeded the cap of KRW 40bn, about USD 29m, set in the agreement). Instrument: share-for-share merger of listed affiliates. Royalty read-through: no rate is stated; the income from rivoceranib, under a resubmitted US application with camrelizumab in liver cancer, moves into one company.

Tanabe Pharma and NeuroDerm (Thursday 19 November). Tanabe Pharma said that it has decided to end the business of its wholly owned Israeli subsidiary NeuroDerm, which it bought in 2017, "現地の法令に従い、段階的に終了する予定" (in stages under local law), citing the optimisation of its portfolio and a focus on the Japanese market. The release does not name a product or state costs; Pharma Japan reported that Tanabe is dropping plans to sell NeuroDerm's Parkinson's disease therapy Onerji in Europe. Instrument: wind-down of a subsidiary. Royalty read-through: none stated.

ExpreS2ion Biotech (Thursday 19 November). ExpreS2ion Biotech Holding (Nasdaq First North Stockholm: EXPRS2) said that "The number of employees will be reduced from 21 to five during 2027", to focus on ES2B-C001, its HER2-targeted active immunotherapy in a Phase 1 breast cancer trial with a primary readout due in the first quarter of 2027.

Annual operating costs fall by about USD 3.2m (SEK 30m) from 2028, restructuring costs are up to about USD 0.5m (SEK 5m), and cash was USD 3.8m (SEK 35.8m) on 31 October; the restructuring "does not by itself finance the Company's operations beyond the Phase I primary readout" and the board "is evaluating financing alternatives". Instrument: workforce reduction. Royalty read-through: none stated; the company keeps its partnered programmes and the ExpreS2 platform.


Royalty-Bearing Positions

Five chains of title the window moved, with the holder of the economics above and the payer below: OLN324, APHEXDA, trofinetide in Japan, aficamten and galinpepimut-S, with the terms published on each link.

Johnson & Johnson, Ollin Biosciences and Blackstone Life Sciences: OLN324 bought for USD 2.2bn upfront, Phase 3 funded for single-digit royalties (Monday 16 November)

Johnson & Johnson (NYSE: JNJ) agreed to acquire Ollin Biosciences, a private company developing OLN324, a VEGF and Ang2 bispecific antibody in Phase 3 for wet age-related macular degeneration and diabetic macular oedema. Blackstone Life Sciences will fund the Phase 3 programme in return for milestones and royalties.

  • The price: "Johnson & Johnson will acquire Ollin for $2.2 billion upfront, with the potential for regulatory and commercial milestone payments up to approximately $1.125 billion." The transaction "is expected to close before the end of 2026".
  • The funding: "Blackstone will pay a total of $750 million to Johnson & Johnson over multiple years to fully fund the Phase 3 development of OLN324." Blackstone said that it "is entitled to certain regulatory and sales milestone payments as well as single digit royalties", and that the agreement "is subject to the acquisition of Ollin by Johnson & Johnson".
  • The licence chain: Innovent Biologics (HKEX: 1801) said that "Ollin's lead program OLN324 (Innovent R&D code: IBI324) was discovered by Innovent and out-licensed to Ollin"; it refers to the other releases for financial details and states none of its own terms.
  • Sources: the Johnson & Johnson release is cited from its investor site, which also states Blackstone's "single digit royalties"; the Blackstone release is cited from Blackstone's own site.
  • Instrument: acquisition for cash with milestones, and a development funding agreement paid in milestones and royalties.
  • Royalty read-through: a new single-digit royalty on OLN324 sales held by Blackstone; Innovent's terms with Ollin, which would pass to Johnson & Johnson, are not disclosed.

Kyorin Pharmaceutical and Acadia Pharmaceuticals: Japanese rights to DAYBUE STIX for USD 30m upfront (Monday 16 November)

Kyorin Pharmaceutical (TSE: 4569) said that it had signed an exclusive agreement with Acadia Pharmaceuticals (Nasdaq: ACAD) to sell DAYBUE STIX (trofinetide) for Rett syndrome in Japan. Kyorin will file for approval and, after price listing, buy the product from Acadia and sell it exclusively.

Acadia said that it "will receive an upfront payment of $30 million and is eligible to receive future regulatory and sales milestone payments as well as a share of net sales of DAYBUE STIX in Japan".

  • The payments: Kyorin pays Acadia "契約一時金として 30 百万米ドル" (an upfront payment of USD 30m) and "薬価収載及び一定の正味売上高の達成によりマイルストンペイメントとして最大 45 百万米ドル等" (milestone payments of up to USD 45m and other amounts on price listing and on reaching certain net sales).
  • The asset: Acadia has completed a Phase 3 trial with results consistent with the LAVENDER trial run in the United States, and the drug holds orphan designation in Japan. It is sold in the United States and Canada and approved in the European Union as DAYBU.
  • Accounting: Kyorin will book the upfront payment as research and development expense in its third quarter; the deal is already in its forecast for the year to March 2027.
  • The licence chain: Acadia holds trofinetide outside North America under its licence from Neuren Pharmaceuticals (ASX: NEU). Acadia's quarterly report of 5 November says it "will be required to pay Neuren tiered royalties from the mid-teens to low-twenties percent of trofinetide net sales outside of North America".
  • Neuren's terms: Neuren said that "for Japan, Neuren is entitled to receive US$15 million following first commercial sale, potential sales milestone payments of up to US$110 million on achievement of escalating annual net sales thresholds, and tiered royalties ranging from mid-teens to low-twenties percentage of net sales", and expects "the anticipated regulatory filing in Japan in 2027, with a potential launch in 2028 subject to regulatory approval".
  • Instrument: exclusive distribution agreement with an upfront payment, milestones, product supply and a share of net sales for Acadia; neither Kyorin nor Acadia states a rate.
  • Royalty read-through: Japanese sales carry Neuren's royalty from the mid-teens to the low twenties, a USD 15m payment on first sale and up to USD 110m in sales milestones; Neuren's notice does not mention a share of Kyorin's upfront payment or milestones.

BioLineRx and Soleus Capital: 80 per cent of the 18 per cent APHEXDA royalty sold for USD 5.6m (Wednesday 18 November)

BioLineRx (Nasdaq: BLRX) said, in a report furnished to the SEC, that it had agreed to sell part of its royalty on APHEXDA (motixafortide) to Soleus Capital "for a one-time payment of $5.6 million". APHEXDA is approved by the FDA to mobilise stem cells for transplantation in multiple myeloma and is sold by Ayrmid Pharma under licence.

  • The agreement: BioLineRx signed a purchase and sale agreement on 17 November with SCOF Motixafortide Holdings, an affiliate of Soleus Capital Management. The purchase price is "$5.6 million at closing, less the Purchaser's documented reasonable transaction expenses capped at $100,000".
  • What is sold: "80% of the royalty payments payable to the Company under the Ayrmid License attributable to sales occurring on or after the closing date". The report adds: "Based on the 18% royalty rate payable to the Company under the Ayrmid License, the 80% interest to be sold to the Purchaser corresponds to a 14.4% royalty on net sales of APHEXDA".
  • What is kept: the remaining 20 per cent, "a 3.6% royalty on net sales", is "attributable to the royalties the Company is obligated to pay to Biokine Therapeutics Ltd., the original licensor of motixafortide". BioLineRx keeps "all rights to receive potential future milestone payments under the Ayrmid License".
  • The lender: Kreos Capital, a BlackRock affiliate, consents and releases its security over the sold royalties. BioLineRx will prepay "$3.0 million" of the loan at closing; about USD 2.0m stays outstanding on a new schedule, and "the minimum cash balance covenant under the Loan Agreement of $4.0 million will be eliminated".
  • Closing: "on or about November 30, 2026". As a condition, "Ayrmid will consent to the sale and agree to remit the Purchased Receivables directly to the Purchaser".
  • The adviser: Chardan Capital Markets "will receive a financial advisory fee of approximately $0.4 million, payable upon the closing".
  • Instrument: royalty purchase of 80 per cent of an existing royalty on an approved product.
  • Royalty read-through: Soleus takes 14.4 per cent of APHEXDA net sales; BioLineRx keeps 3.6 per cent, which passes to Biokine, and the Ayrmid commercial milestones.

Seawolf Therapeutics and Sanofi (Monday 16 November). Seawolf Therapeutics, which develops DNA-based therapies, launched with USD 100m in seed and Series A financing from Versant Ventures, MPM BioImpact, the Novartis Venture Fund, Lilly, CRISPR Therapeutics and others, and with a licence agreement with Sanofi for bleeding disorders and other indications "for up to $1.2 billion in research, development & commercial milestones, as well as tiered royalties on sales of any products resulting from the collaboration".

The upfront payment is not disclosed. Instrument: research collaboration and exclusive licence with milestones and tiered royalties, alongside a private financing. Royalty read-through: a new tiered royalty owed by Sanofi, band not disclosed.

Arcturus Therapeutics and Meiji Seika Pharma (Monday 16 November). Arcturus (Nasdaq: ARCT) said that Meiji bought 2,466,395 shares for an aggregate "$50.0 million", which "represents a premium of 80%" to the average closing price, and took an exclusive licence to the ARCT-154 vaccine in an undisclosed territory.

If the two companies do not sign the definitive pandemic-preparedness licence contemplated by a memorandum of understanding by 31 May 2027, Arcturus must "refund to Meiji 50% of the premium, or approximately $11.1 million". Instrument: equity purchase at a premium, licence and memorandum of understanding. Royalty read-through: none stated in the filing.

TRIMTECH Therapeutics and Biogen (Monday 16 November). TRIMTECH said that Biogen will pay "up to $32 million in upfront and research milestone payments, with total potential payments of up to $411 million, plus royalties" under a collaboration with an option to a global exclusive licence on small-molecule degrader programmes for neurodegenerative disease. Instrument: research collaboration with an option to license.

Royalty read-through: royalties only if Biogen exercises the option; not counted as created.

Stipple Bio and Lilly (Monday 16 November). Stipple Bio, a private Cambridge, Massachusetts, company that designs binders to tumour-specific cell-surface targets, said that Lilly takes "exclusive worldwide rights to develop and commercialize products arising from the collaboration".

Stipple "will receive an upfront payment and an equity investment" and is eligible for "aggregate payments of up to $5.9 billion dollars upon achievement of research, product development and commercialization milestones, as well as tiered royalties on product sales". The upfront and equity amounts are not disclosed. Instrument: research collaboration and exclusive licence with an equity investment. Royalty read-through: a new tiered royalty owed by Lilly, band not disclosed.

ProMIS Neurosciences and Ossianix (Tuesday 17 November). ProMIS Neurosciences (Nasdaq: PMN) said that it had licensed TXP1, Ossianix's brain-shuttle technology, for its Alzheimer's antibody PMN310, with options to apply it to PMN442 and PMN267. "Ossianix will receive an upfront payment and is eligible to receive development, regulatory and commercial milestone payments, as well as royalties on global net sales"; no amounts are given.

ProMIS "does not expect the agreement to change its previously disclosed cash runway through 2027". Instrument: exclusive technology licence with options. Royalty read-through: a new royalty owed by ProMIS to Ossianix, band not disclosed.

Cancer Research UK and Dewpoint Therapeutics (Tuesday 17 November). The two announced a collaboration and licence agreement under which Cancer Research UK's Centre for Drug Development "is responsible for funding, sponsoring and executing a first-in-human Phase 1/2a clinical trial" of DPTX8743, a small-molecule modulator of MYC condensates.

"Dewpoint retains all rights to DPTX8743 and has the right to license the results and intellectual property arising from the collaboration, with Cancer Research UK eligible to receive downstream milestone payments and royalties." No amounts are given. Instrument: clinical development partnership with a licence back. Royalty read-through: a new royalty owed by Dewpoint to Cancer Research UK, band not disclosed.

Pfizer and Starna Therapeutics (Wednesday 18 November). Pfizer (NYSE: PFE) said that it "obtains exclusive rights outside Greater China to develop, manufacture and commercialize three pre-IND in vivo chimeric antigen receptor T-cell (CAR-T) programs that are focused on treating autoimmune diseases", with rights to use Starna's in vivo CAR-T technology in inflammation and immunology and in oncology.

"Starna will receive an upfront payment of $330 million" and "is eligible to receive up to $2.3 billion in milestone payments associated with certain development and commercial milestones, plus royalties on net sales of approved products". Instrument: exclusive licence with options, upfront payment, milestones and royalties. Royalty read-through: a new royalty owed by Pfizer to Starna, band not disclosed.

Genomics and Vertex Pharmaceuticals (Wednesday 18 November). Genomics, an Oxford company that uses large-scale genetic data for target discovery, announced a four-year extension of a collaboration with Vertex that began in 2018. "The total potential contract value exceeds $220 million, for the successful achievement of certain research, development, regulatory and commercial milestones, and tiered royalties on future net sales for any products that may result from this collaboration agreement".

No upfront payment is stated. As an extension of an existing agreement it is named and not counted. Instrument: extension of a research collaboration with milestones and tiered royalties. Royalty read-through: tiered royalties owed by Vertex to Genomics, band not disclosed.

DISCO Pharmaceuticals and AbbVie (Thursday 19 November). DISCO Pharmaceuticals, a private Cologne company that designs AND-gated antibody drug conjugates and T-cell engagers against pairs of tumour surface targets, announced "a strategic collaboration and option-to-license agreement with AbbVie to discover and develop novel AND-gated bispecific therapeutics for solid tumors".

"DISCO will receive $40 million in upfront payments and is eligible for up to $2.5 billion in option, development, and other milestone payments, plus tiered royalties on worldwide net sales." The release names neither the targets nor the number of programmes. Instrument: research collaboration with exclusive licence options, upfront payments, milestones and tiered royalties. Royalty read-through: a new royalty owed by AbbVie to DISCO on any licensed product, band not disclosed.

Guangzhou Innogen and Arcera Life Sciences (Thursday 19 November). Guangzhou Innogen Pharmaceutical Group (HKEX: 2591) announced that its Hong Kong subsidiary granted Arcera Life Sciences "an exclusive licence for an initial" 15 years to efsubaglutide alfa, its GLP-1 drug, in "selected countries in Africa, Latin America, the Middle East and Eastern Europe".

Innogen "is entitled to receive upfront and near-term milestone payments of up to US$38 million (consisting of a non-refundable upfront payment of US$15 million), as well as sales milestone payments and tiered royalties at rates of up to double-digit percentage based on aggregate annual net sales of the Product in the Territory".

"The total potential deal value is over US$1 billion." Instrument: exclusive regional out-licence with upfront, milestones and tiered royalties. Royalty read-through: a new royalty owed by Arcera to Innogen, up to double digits.

Merck and Isomorphic Labs (Thursday 19 November). Merck (NYSE: MRK) announced a research collaboration with Isomorphic Labs, two days after Isomorphic's Series C, to discover small molecules against one oncology target. "Isomorphic Labs will receive an upfront payment from Merck and be eligible for payments based on the achievement of specified research, development, regulatory and commercial milestones, as well as tiered royalties on net sales."

"Isomorphic Labs also receives an option to co-fund development activities in return for elevated royalties." No amounts are disclosed. Instrument: research collaboration with upfront, milestones, tiered royalties and a co-funding option. Royalty read-through: a new royalty owed by Merck to Isomorphic Labs, band not disclosed, rising if Isomorphic co-funds.


Clinical and Regulatory

Summit Therapeutics and Akeso: FDA declines to approve ivonescimab in EGFR-mutated lung cancer (Sunday 15 November)

Summit Therapeutics (Nasdaq: SMMT) said that the FDA "has issued a Complete Response Letter (CRL)" on its application for ivonescimab with platinum chemotherapy in non-small cell lung cancer after EGFR tyrosine kinase inhibitor therapy. Summit licenses the antibody from Akeso (HKEX: 9926).

  • The decision: "The CRL indicates that the BLA cannot be approved in its present form, as the FDA determined that substantial evidence of effectiveness is not established in the absence of a statistically significant overall survival (OS) improvement."
  • The data: in the primary overall survival analysis the combination "showed a positive trend without achieving a statistically significant result"; the release names no resubmission plan.
  • The licence: Summit's quarterly report of 4 November says Akeso is eligible for "regulatory milestones of up to $ 1,050,000" and "commercial milestones of up to $ 3,505,000", in thousands, and "low double-digit royalties on net sales".
  • Timing: Akeso said on 16 November, at the request of the Hong Kong exchange, that "save for the CRL which might have caused the unusual price movements of the shares of the Company", it knows of no reason for the price movements; the announcement gives no figures. Summit filed a current report on 16 November that attaches the release and adds that the progression-free survival benefit, without a statistically significant survival benefit, did "not support a positive benefit-risk profile in support of approval".
  • The letter: the FDA published the letter of 13 November in its database of complete response letters by Wednesday 18 November. It says "Substantial evidence of effectiveness is not established and the benefit-risk profile does not support approval", and that the applicability of the progression-free survival endpoint "to the US population cannot be established as 93% of events (257 of 275 PFS events) occurred in patients enrolled in China."
  • The request: the letter recommends that Summit "Submit results from a new adequate and well-controlled multiregional clinical trial consistent with ICH E17".
  • Instrument: regulatory decision on a licensed product.
  • Royalty read-through: the US regulatory milestones and the low double-digit royalty owed to Akeso in this indication wait on a new multiregional trial or another indication.

Stella Pharma (Monday 16 November). Stella Pharma (TSE: 4888) said that it had obtained approval "本日" (today) to add recurrent meningioma to the label of its boron neutron capture therapy drug Steboronin, "本邦において「再発髄膜腫」を効能又は効果とする医薬品として初めての承認" (the first approval in Japan of a drug for recurrent meningioma).

A second disclosure says that the application of 24 March 2026 for unresectable cutaneous angiosarcoma will be reviewed by the Second Committee on Drugs of the Pharmaceutical Affairs Council on 30 November.

In the investigator-led trial behind the approval, median progression-free survival was "14.4 か月" against "1.4 か月" (14.4 against 1.4 months). Reimbursement of the irradiation fee is expected "2027 年 3 月 1 日から" (from 1 March 2027), and the company expects the effect on the year to March 2027 to be "軽微" (minor). Instrument: approval of a new indication. Royalty read-through: none stated in the disclosure.

Teva and IGALMI (Monday 16 November). Teva Pharmaceuticals, a US affiliate of Teva Pharmaceutical Industries (NYSE: TEVA), said that the FDA had approved IGALMI (dexmedetomidine) sublingual film "for at-home use" in agitation associated with schizophrenia, schizoaffective disorder or bipolar I or II disorder. The release gives no action date.

Teva bought IGALMI from BioXcel in Chapter 11 in October for USD 57.5m upfront and "up to $67.5 million in contingent payments", including time-based payments linked to approval; the approval comes before 21 November, the date the estate's milestone depends on. Instrument: approval of a supplemental application. Royalty read-through: a milestone owed to the BioXcel estate.

Cytokinetics (Monday 16 November). Cytokinetics (Nasdaq: CYTK) said that the FDA had approved a supplemental application adding to the MYQORZO (aficamten) label the data from MAPLE-HCM, the Phase 3 trial against metoprolol in obstructive hypertrophic cardiomyopathy. The indication is unchanged.

Cytokinetics' quarterly report says Royalty Pharma "will now receive 4.5% up to $5.0 billion of worldwide annual net sales of aficamten and 1% above $5.0 billion", and that Cytokinetics receives from Sanofi "tiered royalties in the low-to-high teens range" in China and Taiwan. Instrument: approval of a label update. Royalty read-through: label data supporting sales on which Royalty Pharma holds its royalty.

Revolution Medicines (Monday 16 November). Revolution Medicines (Nasdaq: RVMD) said that the European Commission had approved RASONQUE (daraxonrasib) "for the treatment of adult patients with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy".

Its quarterly report says Royalty Pharma receives "4.55% of annual net sales up to $2.0 billion, 2.50% of annual net sales between $2.0 billion and $4.0 billion, 1.00% of annual net sales between $4.0 billion and $8.0 billion", that the company declined the Tranche 3 payment in October, and that the obligations end on "the fifteenth anniversary of the first commercial sale of an RMC-6236 Product in the United States (or in the European Union for ex-U.S. sales)".

On Thursday 19 November the company reported updated Phase 1/2 data for RASONQUE with gemcitabine and nab-paclitaxel in first-line metastatic pancreatic cancer, presented at the ENA Symposium on 20 November.

In 61 patients, "the confirmed objective response rate was 60.7% (95% confidence interval [CI]: 47.3–72.9)" and "Median progression free survival (PFS) was 12.8 months (95% CI: 10.8–18.4)"; the release names RASolute 303 as the Phase 3 trial these data may support. Instrument: marketing authorisation. Royalty read-through: a first EU sale starts the ex-US royalty term of the Royalty Pharma agreement.

IMPACT Therapeutics and Pharmanovia (Monday 16 November). IMPACT Therapeutics (HKEX: 7630) said that "the European Commission (EC) has granted approval" for senaparib (Sepalna) as first-line maintenance treatment of advanced epithelial ovarian, fallopian tube and primary peritoneal cancer. The announcement states no financial terms.

IMPACT licensed senaparib to Pharmanovia in July for 66 countries, and its release of that licence, published on PR Newswire, says IMPACT may receive near-term regulatory and commercial milestones "with a total amount up to EUR423.5 million", about USD 492m, and "tiered royalties up to the mid-twenties (%) on product net sales". Instrument: marketing authorisation. Royalty read-through: EU sales start Pharmanovia's royalty to IMPACT.

Sobi and Ionis (Tuesday 17 November). Sobi (Nasdaq Stockholm: SOBI) said that the European Commission had approved Tryngolza (olezarsen) "as an adjunct to diet, in combination with other lipid-lowering therapies, for the treatment of adult patients with severe hypertriglyceridaemia". The release does not give the date of the decision.

Ionis discovered olezarsen and sells it in the US, and "Sobi has exclusive rights to commercialise Tryngolza in ex-U.S. geographies except Canada and China". Ionis's release on the licence of March 2025 says it receives "a tiered royalty of up to mid-20% range on annual net sales". Instrument: marketing authorisation of a licensed product. Royalty read-through: EU sales start Sobi's royalty to Ionis.

RaQualia Pharma, HK inno.N and Eurofarma (Tuesday 17 November). RaQualia Pharma (TSE: 4579) said that Eurofarma had obtained approval from Brazil's ANVISA for tegoprazan, the acid blocker RaQualia licensed to HK inno.N, under the name "TREV" in three indications. Eurofarma holds the Brazilian rights under a technology transfer agreement signed with HK inno.N in 2022.

RaQualia holds "HKイノエン社が提携先から受け取る収益の一部を受け取る権利" (the right to receive part of the income HK inno.N receives from its partners) and will receive "一時金" (a lump sum) from HK inno.N, booked in the fourth quarter; no amount is given. Instrument: marketing approval of a sublicensed product. Royalty read-through: Brazilian sales start a stream from Eurofarma to HK inno.N, part of which passes to RaQualia.

Beren Therapeutics (Tuesday 17 November). The FDA approved Lembaz (adrabetadex) to "reduce the risk of death in adult and pediatric patients who weigh at least 7 kg (about 15 pounds) and whose neurological symptoms began before age 6", in infantile-onset Niemann-Pick disease type C. "The FDA granted approval of Lembaz to Mandos, LLC, a subsidiary of Beren Therapeutics, PBC."

The FDA reports a "55% reduction in the risk of death" against an external control. Beren said that "The company received a Priority Review Voucher upon this approval" and that "LEMBAZ will be available at commercial sites nationwide in early December."

Instrument: new drug approval for a private company, with a priority review voucher. Royalty read-through: no licence or royalty stated.

GSK and NELKARMI (Tuesday 17 November). The FDA granted accelerated approval to neladalkib (Nelkarmi, Nuvalent, Inc.) in ALK-positive non-small cell lung cancer after one or more ALK inhibitors. Among patients who had received alectinib only, "ORR was 49% (95% CI: 37, 62)", and 32 per cent after two or more inhibitors and chemotherapy.

GSK said that Nelkarmi is "part of the portfolio from the recent acquisition of Nuvalent, Inc." and that "This approval comes ahead of the original FDA target action date of November 27, 2026". Instrument: accelerated approval. Royalty read-through: no licence or royalty stated.

Amneal, Alvotech and ADVANZ PHARMA (Tuesday 17 November). Amneal Pharmaceuticals (Nasdaq: AMRX) said that "the European Commission (EC) has granted marketing authorization for Adcomfo® (omalizumab), a biosimilar to XOLAIR®". Adcomfo "was developed by Kashiv BioSciences LLC in collaboration with Alvotech"; "Amneal acquired Kashiv in August 2026."

"ADVANZ PHARMA holds the marketing authorization and regional commercialization rights for Adcomfo through its partnership with Alvotech." Amneal's US application for the biosimilar is under FDA review. Instrument: marketing authorisation of a partnered biosimilar. Royalty read-through: none stated in the release.

Regeneron and Alnylam (Wednesday 18 November). Regeneron (Nasdaq: REGN) said that the FDA approved Livsayis (cemdisiran), a small interfering RNA given subcutaneously four times a year, for adults with generalised myasthenia gravis who are anti-acetylcholine receptor antibody-positive. Regeneron develops and sells it "through a worldwide licensing agreement with Alnylam".

Alnylam's quarterly report of 29 October states that it "will receive certain milestone payments upon receipt of regulatory approval for cemdisiran as a monotherapy, and tiered double-digit royalties on net sales"; an EU decision is expected in the second half of 2027. Alnylam said on Thursday 19 November that it "will receive a $25 million payment for the approval, and is eligible to receive tiered, double-digit royalties of up to 15 percent on global net sales".

Instrument: FDA approval of an in-licensed product. Royalty read-through: starts Alnylam's tiered double-digit royalty, capped at 15 per cent, and triggers a USD 25m approval payment.

Sanofi and Infilbray (Wednesday 18 November). The FDA approved Infilbray (venglustat), an oral glucosylceramide synthase inhibitor from Sanofi's Genzyme unit, as the first treatment for the neurological manifestations of type 3 Gaucher disease, in adults and children weighing at least 15 kg; Sanofi announced the approval.

The approval rests on the Phase 3 LEAP2MONO study and carried orphan drug designation and priority review. Instrument: FDA approval of an in-house product. Royalty read-through: none stated; neither release names a partner or a priority review voucher.

AstraZeneca and KYM Biosciences (Thursday 19 November). AstraZeneca (LSE: AZN) said that its application for sonesitatug vedotin, an antibody drug conjugate against Claudin 18.2, "has been accepted and granted Priority Review in the US" for previously treated gastric, gastro-oesophageal junction and oesophageal cancers with CLDN18.2 expression on at least 25 per cent of tumour cells; the FDA decision "is anticipated during the second quarter of 2027".

AstraZeneca "entered into a global exclusive licence agreement with KYM Biosciences" in March 2023, and its completion release of that year gives "an upfront payment of $63m, with potential development and sales-related milestone payments of up to $1.1bn and tiered royalties up to low double digits".

KYM is owned 70 per cent by Keymed Biosciences (HKEX: 2162) and 30 per cent by Lepu Biopharma (HKEX: 2157); neither had announced a milestone on the acceptance by 22 November. Instrument: acceptance of a licensed product's application with Priority Review. Royalty read-through: moves KYM's royalty, up to low double digits, towards a US decision in the second quarter of 2027.

Sanofi and VaxRabeo (Thursday 19 November). Sanofi said that the European Commission approved VaxRabeo, a Vero-cell rabies vaccine, for all ages, "the first marketing authorisation approval for VaxRabeo", after a positive CHMP opinion in September. Instrument: EU approval of an in-house vaccine. Royalty read-through: none stated.

Savara and RTW (Friday 20 November). Savara (Nasdaq: SVRA) said that the FDA "will not meet the Prescription Drug User Fee Act (PDUFA) target action date of November 22, 2026" for molgramostim (MOLBREEVI) in autoimmune pulmonary alveolar proteinosis, and that "no revised action date has been provided by the agency".

Savara's quarterly report says RTW will pay "$ 75.0 million" upon approval "on or before March 31, 2027" for royalties "ranging from 7.0 % to 1.0 % of Net Sales", the top tier "increasing to 9.5 %" if the prior year's sales miss a set level. Instrument: delay of an FDA action date. Royalty read-through: delays the start of the royalty RTW would buy, with RTW's purchase tied to approval by 31 March 2027.

Belite Bio (Friday 20 November). Belite Bio (Nasdaq: BLTE) said that the FDA "has extended the review period" for its application for tinlarebant in Stargardt disease type 1 "by three months, with the extended Prescription Drug User Fee Act (PDUFA) action date being May 12, 2027". It adds that, "if no major deficiencies are identified during FDA’s ongoing review", the FDA plans to communicate proposed labelling requests to the company "by April 12, 2027".

Its IPO prospectus of 2022 says it is "obligated to pay single-digit earned royalties to Columbia University" on net sales, with minimum annual royalties of USD 2.5m and then USD 5m a year after first sale; later amendments were not read. Instrument: extension of an FDA review. Royalty read-through: moves the start of Columbia's royalty by three months.

Capricor Therapeutics and Nippon Shinyaku (Friday 20 November). Capricor Therapeutics (Nasdaq: CAPR) said on 21 November that it "received a Complete Response Letter (CRL)" from the FDA for its resubmitted application for deramiocel in Duchenne muscular dystrophy, two days before its 22 November action date. "The CRL states that the FDA does not consider the data sufficient to establish substantial evidence of effectiveness and cites certain other clinical deficiencies."

Capricor held about USD 198.5m on 30 September, which it believes "is sufficient to fund its planned operations for at least the next 12 months", is reviewing its operating costs, and holds a call on 23 November. Deramiocel holds a Rare Pediatric Disease designation in the United States, so a priority review voucher would follow only an approval.

Its annual report says there is "another potential milestone of $80.0 million due to Capricor upon receipt of marketing approval" from Nippon Shinyaku and that, "Subject to regulatory approval, Capricor will have the right to receive a share of product revenue which falls between 30 and 50 percent". Its quarterly report says Nippon Shinyaku seeks a declaration that the US distribution agreement "remains in full force and effect", while Capricor seeks one that it "has been repudiated and/or is rescinded".

Instrument: complete response letter on a licensed product. Royalty read-through: defers the USD 80m approval milestone and the revenue share of 30 to 50 per cent that Nippon Shinyaku would pay Capricor, under a US agreement that the two companies dispute.

Clinical.

Helus Pharma (Monday 16 November). Helus Pharma said that HLP003, a deuterated psilocin analogue, met the primary endpoint of the Phase 3 APPROACH trial as an adjunctive treatment in major depressive disorder, with a mean reduction in MADRS score of 19.5 points against 11.9 points for placebo at six weeks.

"There were three HLP003 treatment-related serious adverse events in the study", and the company expects "to report topline results from the EMBRACE trial in 4Q 2027". Instrument: Phase 3 readout. Royalty read-through: none identified on HLP003.

CG Oncology (Monday 16 November). CG Oncology (Nasdaq: CGON) said that PIVOT-006, its Phase 3 registrational trial of adjuvant cretostimogene grenadenorepvec in intermediate-risk and high-grade Ta non-muscle invasive bladder cancer, was positive on recurrence-free survival, "with a hazard ratio of 0.32 (95% CI: 0.23, 0.45; p<0.0001)" at a median follow-up of 17 months.

It expects a second BLA submission in this population "in Q2 2027" and will broaden its first BLA, in BCG-unresponsive disease, to include high-grade papillary-only disease, with completion "anticipated in March 2027".

Its quarterly report says it pays Kissei a royalty "on any U.S. sales, in a low-single digit percentage", receives "a royalty on net sales of Licensed Product in the Kissei Territory in the mid-twenties percentage", and receives "a high single-digit royalty" on sales in China from Lepu. Instrument: Phase 3 readout. Royalty read-through: supports sales carrying the three bands.

AriBio, Fosun Pharma and Samjin Pharm (Tuesday 17 November). Samjin Pharm (KRX: 005500), which holds the Korean rights, disclosed that AriBio's oral AR1001 met the primary endpoint of the Phase 3 POLARIS-AD trial in early Alzheimer's disease in the prespecified monotherapy population of 604 patients, with a difference in CDR-SB of "-0.44점" (-0.44 points, p=0.0266, against an allocated alpha of 0.03).

In the overall population of 1,535 patients the difference was "-0.11점" (-0.11 points, p=0.4015), "통계적으로 유의하지 않았습니다" (not statistically significant); the trial succeeds if either population is significant.

Fosun Pharma (HKEX: 2196) said that it has 90 calendar days from receipt of the topline data to decide whether to exercise its exclusive option on worldwide rights outside the territories it already holds, and "尚未就上述全球新增许可区域行使独家选择权" (has not exercised the option). Its option announcement of 14 May set a low double-digit royalty to AriBio on exercise. Instrument: Phase 3 readout on a licensed asset with a pending option. Royalty read-through: a royalty and an exercise payment to AriBio depend on Fosun's decision.

SELLAS Life Sciences (Tuesday 17 November). SELLAS (Nasdaq: SLS) said that the pivotal Phase 3 REGAL trial of galinpepimut-S (GPS) in acute myeloid leukaemia met its primary endpoint, with a median overall survival of 24.0 months against 14.7 months for best available treatment and "a hazard ratio of 0.59 (p=0.035".

SELLAS plans to meet the FDA on "an accelerated filing strategy" and a BLA submission "in the first half of 2027". Its annual report says it agreed "to pay MSK a tiered royalty in the mid-single digits" and that 3D Medicines pays royalties in Greater China "ranging from the high single digits to the low double digits". Instrument: Phase 3 readout on an in-licensed and out-licensed asset. Royalty read-through: supports sales carrying both bands.

Zelgen and AbbVie (Wednesday 18 November). Suzhou Zelgen Biopharmaceuticals (SSE: 688266) disclosed on the evening of 18 November, in a notice dated 19 November, that the randomised pivotal trial of ZG006 (alveltamig), a trispecific antibody, in small cell lung cancer after platinum chemotherapy and at least one other systemic therapy completed its interim analysis, and "独立数据监查委员会(IDMC)对结果审核后判定该项试验达到预设的主要终点" (the independent data monitoring committee judged that the trial met its prespecified primary endpoint).

The trial randomised 115 patients 2:1 against investigator's choice; the primary endpoints are objective response rate assessed by independent review and overall survival, and only the response rate was formally tested at the interim. Zelgen will ask the Center for Drug Evaluation for a pre-BLA meeting and expects "对公司近期业绩不会产生重大影响" (no material effect on near-term results).

The notice does not mention AbbVie, which under the agreement of 30 December 2025 holds rights outside Greater China and owes Zelgen tiered royalties from the high single digits to the mid double digits. Instrument: pivotal interim readout on an out-licensed asset. Royalty read-through: supports a China filing; the AbbVie royalty applies only outside Greater China.

Actinogen Medical (Wednesday 18 November). Actinogen (ASX: ACW) said, in an announcement dated 19 November, that its pivotal XanaMIA trial of emestedastat (Xanamem) in 247 patients with mild to moderate Alzheimer's disease missed its primary endpoint: Xanamem was "numerically, but not statistically, superior to placebo", with a benefit of "0.10 CDR-SB points at Week 36 (p = 0.65)".

It reported a higher rate of no progression in patients over 75 (40 per cent against 22 per cent), is "suspending future phase 3 expenditure" and will explore the results "with potential co-development partners"; it held about USD 13.4m (A$18.9m) in cash and no debt. Instrument: pivotal Phase 2b/3 readout on an in-house asset. Royalty read-through: none.

Merck and Kelun-Biotech (Friday 20 November). Merck said that its Phase 3 TroFuse-015 trial of sacituzumab tirumotecan (sac-TMT) in third-line or later gastro-oesophageal adenocarcinoma "met its primary endpoint of overall survival (OS)" against treatment of physician's choice, and that "Sac-TMT did not meet the secondary endpoint of progression-free survival (PFS)"; no hazard ratio was given.

"Kelun-Biotech has granted Merck the exclusive rights to develop, manufacture and commercialize sac-TMT" outside Greater China; Kelun's royalty rate is not stated. Merck's quarterly report for the second quarter says Blackstone Life Sciences funds sac-TMT development for "low-to-mid single-digit royalties on net sales". Instrument: Phase 3 readout on an in-licensed asset. Royalty read-through: supports sales on which Kelun-Biotech and Blackstone Life Sciences hold royalties.

Courts.

The eight court items of the window, by date of filing, ruling or first public appearance. Gold sits on a licence, royalty, milestone or revenue interest, as in Bayer's suit against MSN over generic STIVARGA, on which Amgen reported a 20 per cent royalty in 2014.

Genentech, Roche and PTC Therapeutics v. Zydus (filed Friday 13 November, public on Monday 16 November). Genentech, Hoffmann-La Roche and PTC Therapeutics sued three Zydus companies in the District of New Jersey (No. 2:26-cv-14713) over abbreviated application No. 222036 for generic EVRYSDI (risdiplam) tablets, per the docket. The plaintiffs "received written notice of the Zydus Tablets ANDA by letter dated October 2, 2026", and "This action is being commenced within 45 days of receipt".

Zydus certified under Paragraph IV against five patents and under Paragraph III against US Patent 9,586,955; two of the asserted patents are "duly assigned to Roche and PTC". PTC sold most of its EVRYSDI royalty to Royalty Pharma and, after the agreement of October 2023, kept "approximately 19% of the Evrysdi royalty stream" pending option exercises, per its current report. Instrument: Hatch-Waxman complaint on a marketed product. Royalty read-through: the generic entry date bounds the royalty Royalty Pharma and PTC receive on Roche's sales.

Dr Reddy's Laboratories v. Boehringer Ingelheim (Tuesday 17 November). The Patents Court of England and Wales held ([2026] EWHC 2944 (Pat), HP-2024-000037) that Boehringer's compound patent on empagliflozin, sold as Jardiance, "was always invalid for obviousness and/or insufficiency arising from lack of plausibility" and that the supplementary protection certificate based on it, which would have run to 26 November 2029, "was and is invalid as a result".

The court held a crystalline-form patent "valid while in force", which Dr Reddy's would have infringed but for an interim injunction; that patent has expired. Time for permission to appeal runs from a form-of-order hearing before the end of Michaelmas term 2026. Instrument: patent judgment on a marketed product. Royalty read-through: no royalty holder is named; the judgment removes UK exclusivity on Jardiance three years early, subject to appeal.

Astellas and Medivation v. Apotex (filed Monday 16 November). Astellas Pharma, two US Astellas companies and the Pfizer subsidiaries Medivation LLC and Medivation Prostate Therapeutics LLC sued two Apotex companies in the District of New Jersey (No. 3:26-cv-14777) over "ANDA No. 221907" for generic enzalutamide tablets, sold as Xtandi, per the docket. The complaint asserts US Patents 11,839,689, 12,502,357 and 12,161,628.

It says that "Apotex's Notice Letter does not allege invalidity under 35 U.S.C. §§ 101, 102, 103, or 112, or unenforceability of any claim of the '689 and '357 patents", that "API was granted an exclusive license to the Xtandi® patents", and that "Xtandi® tablets are sold and co-promoted by APUS and Pfizer Inc."

Royalty Pharma's annual report for 2025 lists a "Slightly less than 4% royalty" on Xtandi with an estimated duration of 2027 to 2028, and USD 197m of royalty receipts on the product in 2025. Instrument: Hatch-Waxman complaint on a marketed product. Royalty read-through: Royalty Pharma's stated royalty term ends in 2027 to 2028; the complaint does not mention it.

Baxter v. Sagent and Gland Pharma (filed Thursday 19 November). Baxter sued Sagent Pharmaceuticals and Gland Pharma in the District of Delaware (No. 1:26-cv-01490) over abbreviated new drug application No. 219692 for Norepinephrine Bitartrate in 5% Dextrose Injection, which relies on Baxter's NDA No. 214313, asserting US Patents 12,290,494 and 12,714,681.

The complaint says that "the FDA approved Defendants' ANDA on August 11, 2025" and that "Sagent has informed Baxter that it intends to distribute and sell Defendants' ANDA Product throughout the United States beginning on or after December 1, 2026." Instrument: patent infringement complaint against an approved generic of a marketed product. Royalty read-through: none stated in the complaint.

Halozyme v. Merck (Thursday 19 November). Halozyme Therapeutics (Nasdaq: HALO) said that the Munich Higher Regional Court "overturned the decision issued in December 2025, ordering Merck to refrain from distributing and offering Keytruda SC in Germany". Halozyme "will immediately file an infringement lawsuit against Merck in Germany seeking permanent relief".

The order itself is not published. A Dutch court's prohibition of October 2026 covering eight European countries stands, and Halozyme says its MDASE patents "are not included in Halozyme's ENHANZE licensing program", so the case does not affect ENHANZE. Instrument: appellate ruling on a preliminary injunction over a marketed product. Royalty read-through: none stated in the release; Keytruda SC uses a hyaluronidase that Merck licensed from Alteogen, and the ruling reopens German sales pending a full action.

CHP III v. Cravatt (Thursday 19 November). The Delaware Supreme Court, sitting en banc, affirmed (No. 70, 2026) the Court of Chancery's dismissal (C.A. No. 2024-0867) of a suit by Vividion investor CHP III against the company's founders, Belharra Therapeutics and others. The order recites that, "To minimize royalty and milestone payments Bayer would owe Scripps under the License Agreement", a Scripps patent application was released before Bayer's USD 2bn purchase of Vividion and later licensed to Belharra.

The court held the claims derivative, so the merger extinguished the investor's standing. Instrument: appellate ruling in a dispute over a royalty-bearing university licence. Royalty read-through: Bayer's royalty and milestone obligations to Scripps are not changed by the ruling.

Vanda Pharmaceuticals v. MSN (settled Monday 16 November, disclosed Friday 20 November). Vanda (Nasdaq: VNDA) disclosed that it had settled its District of Delaware suit (No. 1:24-cv-00815) over MSN's application for a generic of HETLIOZ LQ (tasimelteon oral suspension). "Vanda granted MSN a non-exclusive, royalty-free license" from a date that "is in the first quarter of 2040, but MSN may be able to enter the market earlier under certain circumstances".

MSN "acknowledged that the patents asserted in the Litigation are valid and enforceable with respect to its ANDA product", and a consent judgment was entered on 19 November (D.I. 141). Instrument: Hatch-Waxman settlement with a royalty-free licence. Royalty read-through: none; the licence is royalty-free.

Bayer HealthCare v. MSN (filed Thursday 19 November, public on Friday 20 November). Bayer HealthCare LLC and Bayer HealthCare Pharmaceuticals sued MSN Pharmaceuticals and MSN Laboratories in the District of Delaware (No. 1:26-cv-01502) over "ANDA, No. 221953" for generic regorafenib tablets, sold as STIVARGA, asserting "U.S. Patent Nos. 8,637,553 (“the ’553 patent”); 9,458,107 (“the ’107 patent”); and 9,957,232 (the “’232 patent”)", per the docket.

MSN gave notice "By letter dated October 6, 2026", and Bayer asks that approval of MSN's product be "not earlier than the expiration date of the ’553 patent, inclusive of any extension(s)". Amgen's annual report for 2013 says that with Onyx it "acquired the right to receive a 20% royalty on Stivarga® global net sales from Bayer"; Amgen's annual report for 2025 does not mention Stivarga.

Instrument: Hatch-Waxman complaint on a marketed product. Royalty read-through: the generic entry date bounds the royalty Amgen reported on Stivarga sales, if that royalty remains in force.

Public capital and debt.

Akebia Therapeutics and Symbiotic Capital (Monday 16 November). Akebia (Nasdaq: AKBA) reported a senior secured term loan facility "of up to $140.0 million" with lenders led by Symbiotic Capital, signed on 12 November; "A first tranche term loan of $60.0 million" was funded, with up to USD 80.0m more in discretionary tranches.

Interest is "the greater of (i) 11.5% and (ii) the prime rate ... plus 4.5%, subject to a maximum rate of 15.0% per annum", and the facility matures on 12 November 2031; the loan refinanced Akebia's USD 55.0m Kreos loan. Instrument: senior secured term loan with warrants. Royalty read-through: a first lien on substantially all assets, including royalty and licence revenue.

JW (Cayman) Therapeutics (Sunday 15 November). JW Therapeutics (HKEX: 2126), which markets the CAR-T therapy Carteyva, agreed to issue "61,185,465 Subscription Shares at the Subscription Price of HK$2.615 per Subscription Share, for an aggregate Subscription Amount of HK$160.00 million", about USD 20.6m, to China Hongqiao Holdings and Novo Vista Limited Partnership.

The price "represents a discount of approximately 2.97%" to the last close, and completion needs NMPA approval of "the use of its in-house produced lentiviral vector in the commercial manufacture of Carteyva". About 40 per cent of the proceeds goes to the in vivo CAR-T pipeline. Instrument: subscription of new shares under the general mandate. Royalty read-through: none stated in the announcement.

Sinotau Pharmaceutical (Sunday 15 November). Beijing Sinotau International Pharmaceutical Technology, a radiopharmaceutical company, launched its Hong Kong initial public offering: "6,561,000" H shares in all, "656,100" in Hong Kong and "5,904,900" internationally, at a maximum offer price of HK$68.0 (about USD 8.74) and an expected minimum of HK$52.0 (about USD 6.68).

Dealings under stock code 9941 are expected to start on Tuesday 24 November, with allocation results due by 23 November; the announcement does not state the proceeds. Instrument: global offering of H shares, subject to an over-allotment option. Royalty read-through: none stated in the announcement.

Lytix Biopharma (Wednesday 18 November). Lytix Biopharma (Euronext Growth Oslo: LYTIX) said that it had "raised aggregate gross proceeds of NOK 80 million", about USD 7.8m, in a private placement at NOK 8.00 a share and a retail offer through Nordnet. "DNB Carnegie, a part of DNB Bank ASA, is acting as sole bookrunner", and a subsequent offering of up to NOK 15m, about USD 1.5m, follows at the same price.

The proceeds go to preparing a Phase III study of ruxotemitide in neoadjuvant melanoma, and "The Phase III study itself will require additional financing and/or a partner." Verrica Pharmaceuticals' quarterly report says it holds an exclusive Lytix licence to VP-315 in dermatological cancers and owes "tiered royalties based on worldwide annual net sales ranging in the low double digits to the mid-teens".

Instrument: private placement and retail offer of new shares. Royalty read-through: Lytix receives the VP-315 royalty from Verrica if a product reaches market.

SELLAS Life Sciences (Thursday 19 November). SELLAS (Nasdaq: SLS) priced "11,538,462 shares of its common stock at a public offering price of $13.00 per share", for "gross proceeds to SELLAS expected to be $150.0 million", two days after its Phase 3 REGAL result (Clinical), with a 30-day option for the underwriters on 1,730,769 more shares and closing expected on 20 November.

The final prospectus supplement, filed on 19 November, puts net proceeds at "approximately $140.6 million, or approximately $161.8 million if the underwriters exercise their option ... in full".

"J.P. Morgan and TD Cowen are acting as the lead book-running managers for the offering", with Mizuho as book-running manager and A.G.P./Alliance Global Partners and Maxim Group as lead managers.

SELLAS's current report, filed on 20 November, says it "expects to receive net proceeds from the offering of approximately $161.8 million, which includes the proceeds from the Underwriters' exercise in full of their option"; Mintz, Levin, Cohn, Ferris, Glovsky and Popeo gave the legal opinion.

SELLAS said on 20 November that it had closed the offering of 13,269,231 shares, "which includes the exercise in full by the underwriters of their option", and that "The aggregate gross proceeds to SELLAS from this offering were $172.5 million".

Instrument: underwritten public offering of common shares. Royalty read-through: none in the offering; SELLAS owes Memorial Sloan Kettering a mid-single-digit royalty on galinpepimut-S.

Jiangsu Recbio Technology and Yangtze River Pharmaceutical (Wednesday 18 November). Jiangsu Recbio (HKEX: 2179), a vaccine company, said that a wholly owned subsidiary of Yangtze River Pharmaceutical, which holds about 22.86 per cent of its shares, will subscribe for "70,139,343 new H Shares at the Subscription Price of HK$5.00 per Subscription Share for a total consideration of HK$350,696,715", about USD 45m, a premium of about 28.21 per cent to the last close.

Thirty per cent of the net proceeds go to "pre-launch preparation and commercial production arrangements for the recombinant shingles vaccine REC610", 30 per cent to the nine-valent HPV vaccine REC603 and 20 per cent to repaying financial institutions. The group's holding would rise to about 33.16 per cent, so completion needs a whitewash waiver and independent shareholder approval. Instrument: connected subscription of new H shares under a specific mandate. Royalty read-through: none.

Crystal Crop Protection (Wednesday 18 November). Crystal Crop Protection, which describes itself as "a crop solutions company with agrochemicals and seeds at the core of our offerings", opened its initial public offering on the NSE and BSE on 18 November and closed it on 20 November, according to its abridged prospectus on the SEBI site.

The offer combines a fresh issue "aggregating up to ₹ 3,550.03 million", about USD 40.3m, with an offer for sale of "Up to 3,702,694 Equity Shares", after a pre-IPO placement of INR 842.87m, about USD 9.6m, at INR 272.07 a share.

Of the net proceeds, INR 2,479.42m, about USD 28.2m, goes to "Repayment/pre-payment, in full or part, of certain borrowings", and IIFL Capital, DAM Capital and Motilal Oswal are the book running lead managers. Brokers reported a price band of INR 259 to INR 272 and a total issue of about INR 4,555m, about USD 51.8m; the abridged prospectus leaves both blank. Instrument: initial public offering with a fresh issue and an offer for sale. Royalty read-through: none stated.

Private funding.

Bravera Bio (Monday 16 November). BeOne Medicines (HKEX: 6160) disclosed that it will join a Series A of "17,109.3 万美元" (USD 171.093m) in Bravera Bio, a San Carlos oncology company founded in April 2026, at "每股认购价格为 9.3333 美元" (USD 9.3333 a share), in three closings, the later two depending on milestones.

BeOne invests USD 19.5m, alongside venBio, TCG Crossover, Janus Henderson, Baker Brothers and others, and Bravera will issue 3,765,315 common shares to an unnamed licensor under its licence agreement. Instrument: Series A preferred shares. Royalty read-through: none disclosed; the licence terms are not stated.

Galvanize Therapeutics (Monday 16 November). Galvanize, which sells a cleared pulsed electric field ablation system, announced "the closing of an oversubscribed $130 million Series D financing" led by HealthQuest Capital. Instrument: Series D equity. Royalty read-through: none.

Remedy Robotics (Monday 16 November). Remedy Robotics, which develops a robotic system for endovascular procedures, raised "$62 million in Series B funding". "DCVC led the Series B", with UC Investments, Skip Capital and Hostplus among new investors; the funds support "a planned pivotal clinical trial in partnership with the University of California". Instrument: Series B equity. Royalty read-through: none.

Commit Biologics (Tuesday 17 November). Commit Biologics, a Copenhagen company developing complement-engaging bispecific antibodies, announced "the completion of a $60 million (€54 million) seed financing round". "The final close was led by Ackermans & van Haaren", with AbbVie Ventures and M Ventures as new investors and Bioqube Ventures, Korys and Novo Holdings as existing ones.

The release does not split the amount between closings; the proceeds take the first candidate, COM002, through IND filing. Instrument: seed equity. Royalty read-through: none.

Isomorphic Labs (Tuesday 17 November). Isomorphic Labs, an AI drug discovery company, announced that it "has raised $5 Billion in Series C funding". "The round was co-led by Greenoaks and Sequoia Capital", with Andreessen Horowitz and Alphabet, and all existing investors took part, including the UK Sovereign AI Fund. Instrument: Series C equity. Royalty read-through: none.

Marrow Therapeutics (Tuesday 17 November). Marrow Therapeutics, which develops bone marrow-targeted therapies for blood disorders, launched "with a combined $173 million in Series A and B funding". "The $53 million Series A financing was co-led by Scion Life Sciences and venBio", and OrbiMed led the USD 120m Series B with RTW Investments, KKR and others. Instrument: Series A and B equity. Royalty read-through: none.

Onward Therapeutics (Tuesday 17 November). Onward Therapeutics, a clinical-stage oncology company based in Taipei with teams in Switzerland and France, said that it had "closed its NT$900 million (approximately US$28 million) Series B financing. The round was raised in two closings, the second of which took place in October 2026."

Existing shareholders, "including CDIB Capital Healthcare Ventures and Hong Kong Chlitina International", took part alongside new investors, and the company plans to register on the Taipei Exchange's Emerging Stock Board by the end of 2027. Instrument: Series B equity. Royalty read-through: none.

Science Corporation (Tuesday 17 November). Science Corporation, which sells the PRIMA retinal implant in Europe, said on 17 November that it "has raised a $400 million Series D financing with participation from Khosla Ventures, the Ackman Oxman Institute, Tenet Healthcare, 885 Capital, Y Combinator, and PLC Neurotech, among others." The post gives no valuation and no lead investor.

The round brings the total raised since 2021 to "more than $900 million" and follows the European launch of PRIMA, "the first brain-computer interface to be CE marked to restore form vision"; Science will prepare a US launch under the Humanitarian Device Exemption pathway. Instrument: Series D equity. Royalty read-through: none.

VitriVax (Wednesday 18 November). VitriVax, a Boulder vaccine formulation company, announced "the close of an oversubscribed $87 million Series C financing". "The investment was co-led by F-Prime, NEA, RA Capital Management, and Sanofi Ventures with participation from Eli Lilly and Company as well as other existing investors."

The proceeds take its Lyme disease vaccine candidate into a first-in-human trial. Instrument: Series C equity. Royalty read-through: none.

Seawolf Therapeutics' USD 100m launch financing is under Royalty-Bearing Positions with its Sanofi licence.

Sofinnova Partners (Monday 16 November). Sofinnova Partners announced the final close of Sofinnova Crossover II at "€725 million ($815 million USD)", above its original target. The fund "will focus primarily on European clinical-stage biopharma and medtech companies seeking capital to advance toward commercialization" and "has already backed Hemab Therapeutics, CellCentric and Neurent Medical".

It expects to invest in about 15 companies. Not counted in the private funding total. Instrument: final close of a crossover fund. Royalty read-through: none.

Capital announced, priced or received between 15 and 22 November: about USD 7.88bn across 24 flows. Venture syndicates lead with USD 6.21bn, and Isomorphic Labs' USD 5bn Series C is the largest single flow, ahead of Blackstone's USD 750m of Phase 3 funding for Johnson & Johnson's OLN324. M&A prices and the Sofinnova fund close are left out.

The same capital by instrument. Equity makes up 83 per cent of the total and Blackstone's OLN324 funding 10 per cent; licence upfronts were USD 415m across four payments, 5 per cent of the total.

M&A and licence prints between 15 and 22 November on a square-root scale, upfront against total. Fifteen publish a figure, among them the Genomics extension with Vertex, which is named and not counted, and nine publish no consideration; Johnson & Johnson's USD 2.2bn upfront for Ollin Biosciences is the largest cash print, and Lilly's licence from Stipple Bio, up to USD 5.9bn in milestones, the largest headline.

Upfront as a share of the published total, for the five licences that publish both. Kyorin's agreement with Acadia pays 40.0 per cent on signing, and AbbVie's options with DISCO and Arcera's licence from Innogen 1.6 and 1.5 per cent. Royalties sit outside every total.


League Tables

Financial advisers, bookrunners, counsel, buyers and funders, and courts named in the issue for 15 to 22 November, counted once per mandate. Goodwin Procter leads counsel with two mandates, for Calytrix and Rapid Micro Biosystems, five banks managed the SELLAS offering and three the Crystal Crop Protection offering, and the District of Delaware heard three of the eight court items.

Buyers and funders. Blackstone Life Sciences: USD 750m of development funding for OLN324 (Johnson & Johnson). Soleus Capital: USD 5.6m for 80 per cent of the APHEXDA royalty (BioLineRx).

Financial advisers. Centerview Partners (Calytrix, sale to Lilly); Perella Weinberg Partners (Rapid Micro Biosystems, sale to Merck KGaA); Leerink Partners (Mayne Pharma, sale to Gedeon Richter); H.C. Wainwright (Gedeon Richter); Canaccord Genuity (Aytu, sale to Rosemont); Bourne Partners (Rosemont); DNB Carnegie (Lytix Biopharma, sole bookrunner); Chardan Capital Markets (BioLineRx, royalty sale to Soleus Capital); China International Capital Corporation Hong Kong Securities (Jiangsu Recbio, subscription); J.P. Morgan and TD Cowen (SELLAS, lead book-running managers), Mizuho (SELLAS, book-running manager), A.G.P./Alliance Global Partners and Maxim Group (SELLAS, lead managers); IIFL Capital (Crystal Crop Protection, book running lead manager); DAM Capital (Crystal Crop Protection, book running lead manager); Motilal Oswal (Crystal Crop Protection, book running lead manager).

Courts. District of New Jersey, 2 (Genentech, Hoffmann-La Roche and PTC Therapeutics v. Zydus, No. 2:26-cv-14713; Astellas Pharma v. Apotex, No. 3:26-cv-14777); Patents Court of England and Wales, 1 (Dr Reddy's Laboratories (UK) v. Boehringer Ingelheim, HP-2024-000037); Oberlandesgericht München, 1 (Halozyme v. Merck, preliminary injunction appeal; case number not published); Delaware Supreme Court, 1 (CHP III v. Cravatt, No. 70, 2026); District of Delaware, 3 (Baxter v. Sagent Pharmaceuticals and Gland Pharma, No. 1:26-cv-01490; Vanda Pharmaceuticals v. MSN Pharmaceuticals, No. 1:24-cv-00815; Bayer HealthCare v. MSN Pharmaceuticals, No. 1:26-cv-01502).

Legal counsel. Goodwin Procter (Calytrix; Rapid Micro Biosystems); Paul, Weiss, Rifkind, Wharton & Garrison (Lilly); Gilbert + Tobin and Arnold & Porter (Mayne Pharma); Johnson Winter Slattery and Hogan Lovells Cadwalader (Gedeon Richter); Dorsey & Whitney (Aytu); Ropes & Gray (Rosemont); Mintz, Levin, Cohn, Ferris, Glovsky and Popeo (SELLAS).

Currencies

Currency and language note: all amounts are given in US dollars. Where a source uses another currency, the converted figure comes first and the original follows in brackets, at approximately EUR 0.86, SEK 9.50, NOK 10.30, CHF 0.885, DKK 6.40, GBP 0.74, JPY 146, KRW 1,370, CNY 7.10, HKD 7.78, TWD 32.0, AUD 1.41 and INR 88 per US dollar, being late September 2026 rates. Where a source published its own conversion, that figure is used. Quotations from sources in other languages are given in our English translation.


All information in this report was accurate as of the research date and is derived from publicly available sources including SEC filings, Hong Kong Stock Exchange announcements, National Stock Exchange of India filings, European Medicines Agency and Food and Drug Administration records, United States patent assignment records, company press releases and financial news reporting. Information may have changed since publication. This content is for informational purposes only and does not constitute investment, legal, or financial advice. The author is not a lawyer or financial adviser.

Subscribe to P05.org

Don’t miss out on the latest issues. Sign up now to get access to the library of members-only issues.
jamie@example.com
Subscribe